Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08BDI
|
|||
Former ID |
DNC005459
|
|||
Drug Name |
N-(5-o-Tolyl-furan-2-carbonyl)-guanidine
|
|||
Synonyms |
CHEMBL192634; N-(5-o-Tolyl-furan-2-carbonyl)-guanidine
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C13H13N3O2
|
|||
Canonical SMILES |
CC1=CC=CC=C1C2=CC=C(O2)C(=O)N=C(N)N
|
|||
InChI |
1S/C13H13N3O2/c1-8-4-2-3-5-9(8)10-6-7-11(18-10)12(17)16-13(14)15/h2-7H,1H3,(H4,14,15,16,17)
|
|||
InChIKey |
ACPWXEWIQCMXFE-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Sodium/hydrogen exchanger 1 (SLC9A1) | Target Info | Inhibitor | [1] |
KEGG Pathway | cAMP signaling pathway | |||
Cardiac muscle contraction | ||||
Adrenergic signaling in cardiomyocytes | ||||
Regulation of actin cytoskeleton | ||||
Thyroid hormone signaling pathway | ||||
Salivary secretion | ||||
Gastric acid secretion | ||||
Pancreatic secretion | ||||
Bile secretion | ||||
Proteoglycans in cancer | ||||
Pathway Interaction Database | Endothelins | |||
RhoA signaling pathway | ||||
ErbB1 downstream signaling | ||||
Signaling mediated by p38-alpha and p38-beta | ||||
Reactome | Hyaluronan uptake and degradation | |||
WikiPathways | Regulation of Actin Cytoskeleton | |||
G Protein Signaling Pathways | ||||
Glycosaminoglycan metabolism | ||||
Osteoclast Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.